Twist Bioscience Corporation

TWST

CIK 0001581280 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$111M
↑+19.3% +$18Mvs FY2025 (Q1)
Gross Profit
$57M
↑+24.1% +$11Mvs FY2025 (Q1)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
69/100
  • Profitability
    0ROIC -22.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.64 (above 1.5 = solid)
  • Leverage
    100D/E 0.00 (under 0.5 = conservative)
  • Efficiency
    31Asset Turnover 0.60x (1.0+ = capital-efficient)
  • Growth
    81Revenue YoY +19.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -41.4% · trend +29.5pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$39M
investment in PP&E
Stock-based comp (TTM)
$64M
non-cash dilution

Balance sheet · 2026-03-31

latest filed snapshot
Total assets
$676M
everything owned
Total liabilities
$221M
everything owed
Stockholders' equity
$455M
shareholder claim
Net debt
$-122M
Net cash position ($122M)

Recent performance · 35 quarters

Revenue↑+19.3% +$18M
$111M
Net Income↓-11.9% -$5M
$-44M
Free Cash Flow↓-90.3% -$4M
$-8M
Operating Margin↑+3.4pts
-41.4%

Drill down